Home
│
中文
│
English
│
UBI
│
UBIA
│
UBIOCMO
Message from Chairperson
Company Overview
History
Management Team
Board of Directors
Corporate Responsibility
Core Technologies
Pipelines
Products
Manufacturing Facilities
Contract Manufacturing Services
Contract Research & Development Services
Press Release
Media & News
Events
Presentations
Chairperson’s Daily Digest
Shareholder Services
Material information
Investor Conference
Corporate Governance
Locations
Contact Us
Careers
Links
Press Release
Media & News
Events
Presentations
Chairperson’s Daily Digest
•
UBIA Group and Development Center of Biotechnology Co-Develop a New Targeted Cancer Therapy Drug(2016/02/18)
•
UBIP Emerging Stock Board Pre-Listing Presentation is Held Today (2016/1/21)
•
Phase I Clinical Summary Report of UBIP’s EPO Biosimilar was Approved by Taiwan FDA (2016/01)
•
UBIP Honored by Taiwan President Ma for New Drug Development and Branding (2015/12/30)
•
Phase III Clinical Trial for EPO Biosimilar UB-851 is Approved to Proceed by Taiwan FDA (2015/12)
•
UBIP Awarded the First Prize of Outstanding Enterprise, the 12th National Brand Yushan Award ( 2016/11/05 )